Change over period: —
NSE · THYROCARE
THYROCARE
-22.4% from the 52-week high · +44.1% above the low
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 1,645 full-time employees. The company went IPO on 2016-05-09. The firm has diagnostic chains that conduct a range of medical diagnostic tests and profiles of tests that is focused on early detection and management of health disorders and diseases. The firm's segments include Diagnostic Testing Services, Imaging Services and Others. The Diagnostic Testing Services segment includes diagnostic and testing services, selling of consumables used for collection and promotion of pathology. The Imaging Services includes diagnostic and imaging services, selling of radio-pharmaceutical, selling of consumables for reporting. The Others segment include the sale of testing equipment and consumables, and selling of glucometer and glucostrips under the brand, Sugarscan. The firm has a centralized fully automated diagnostic testing laboratory, regional processing laboratories, a medical cyclotron facility and PET-CT facilities across India.
The short version. THYROCARE reported revenue of ₹271 crore for Sep 2026, up 24.9% from a year earlier. Net profit was ₹16 crore (down 66.7% year on year). Return on equity was 27.9% in Mar 2026. Promoter holding was 51.02% in Sep 2026, down 20.04 points over 8 quarters.
1 · The price
How has the stock traded?
THYROCARE trades 22.4% below its 52-week high and 44.1% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹271 cr.
Sep 2026 net profit of ₹16 cr.
16.3 pts lower than a year earlier.
Revenue compounded at 16.5% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 271 | 240 | 224 | 196 | 217 | 193 | 187 | 166 |
| Net profit | 16 | 52 | 47 | 29 | 48 | 39 | 22 | 19 |
| Net margin % | 5.9 | 21.7 | 21.0 | 14.8 | 22.2 | 20.2 | 11.6 | 11.5 |
| EPS (₹) | 1.0 | 3.28 | 2.96 | 1.82 | 3.02 | 2.45 | 1.36 | 1.2 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 829 | 687 | 572 | 527 | 589 | 495 | 433 | 403 |
| Net profit | 163 | 92 | 71 | 64 | 176 | 113 | 88 | 85 |
| Net margin % | 19.7 | 13.3 | 12.4 | 12.2 | 29.9 | 22.9 | 20.4 | 21.1 |
| EPS (₹) | 10.24 | 5.76 | 4.45 | 4.06 | 11.1 | 7.13 | 5.58 | 5.38 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 27.9% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 27.9 | 16.7 | 13.4 | 12.1 |
| Return on capital % | 33.6 | 26.3 | 18.0 | 16.2 |
| EBITDA margin % | 32.2 | 29.2 | 25.3 | 24.0 |
| Net margin % | 19.3 | 13.0 | 12.2 | 12.0 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 16.5% | 10.8% |
| Profit CAGR | 36.2% | 7.6% |
4 · The owners
Who holds it, and are they adding?
Down 20.04 pts over 8 quarters.
Up 6.6 pts over 8 quarters.
Up 11.25 pts over 8 quarters.
+9 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 71.06 | 71.06 | 71.06 | 71.06 | 60.93 | 60.92 | 60.92 | 51.02 | -20.04 |
| FII | 2.77 | 2.41 | 3.23 | 4.85 | 4.95 | 5.37 | 5.44 | 9.37 | +6.6 |
| DII | 14.67 | 14.97 | 14.54 | 13.47 | 20.51 | 20.99 | 20.92 | 25.92 | +11.25 |
| Public | 11.49 | 11.56 | 11.17 | 10.63 | 13.61 | 12.71 | 12.72 | 13.7 | +2.21 |
Mutual fund holdings · Oct 2026
42 schemes hold this stock
33 the month before.
- DSP Healthcare Fund2.84% of NAV
- NIPPON INDIA PHARMA FUND1.93% of NAV
- ADITYA BIRLA SUN LIFE BUSINESS CYCLE FUND1.88% of NAV
- ICICI Prudential Dividend Yield Fund1.79% of NAV
- HSBC Midcap Fund1.54% of NAV
- Shriram Multi Sector Rotation Fund1.52% of NAV
- ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND1.49% of NAV
- ADITYA BIRLA SUN LIFE ELSS TAX SAVER FUND1.43% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for THYROCARE are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about THYROCARE
What is the THYROCARE share price?
THYROCARE (THYROCARE) last closed at ₹504.85, up 0.25% on the day. Its 52-week range is ₹349.55 to ₹649.35.
What is the market cap of THYROCARE?
THYROCARE has a market capitalisation of about ₹8,013 crore. Its price-to-earnings ratio is 56.3.
How are THYROCARE's latest results?
THYROCARE reported revenue of ₹271 crore for Sep 2026, up 24.9% from a year earlier. Net profit was ₹16 crore (down 66.7% year on year). Return on equity was 27.9% in Mar 2026. Promoter holding was 51.02% in Sep 2026, down 20.04 points over 8 quarters.
Who owns THYROCARE?
As of Sep 2026, shareholding was: Promoter 51.02%, FII 9.37%, DII 25.92%, Public 13.7%.
How many mutual funds hold THYROCARE?
42 mutual fund schemes held THYROCARE in October 2026. That compares with 33 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 23 Jun 2026 · Final Dividend - Rs. 7
- 28 Nov 2025 · Bonus issue 2:1
- 24 Oct 2025 · Interim Dividend - Rs. 7
- 25 Jul 2025 · Final Dividend - Rs. 21
- 16 Aug 2024 · Final Dividend - Rs. 18
- 20 Apr 2023 · Interim Dividend - Rs. 18
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.